NCT05864170View on ClinicalTrials.gov

the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
β-thalassemia
Interventions
BIOLOGICAL

β-globin restored autologous hematopoietic stem cells

β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q

Trial Locations (1)

Unknown

RECRUITING

Shenzhen University General Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen Hemogen

INDUSTRY